Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 4,940,912 new fully paid ordinary shares, following the exercise or conversion of options or other convertible securities. The issuance and listing of these additional shares modestly increases the company’s free float and share capital, potentially enhancing liquidity for investors and signaling ongoing utilisation of equity-linked incentives or financing instruments.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code PAR. The company operates in the life sciences sector, developing pharmaceutical therapies, with its securities traded on the Australian equity market.
Average Trading Volume: 965,689
Technical Sentiment Signal: Sell
Current Market Cap: A$143.6M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.